Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
13.40
-0.51 (-3.67%)
Mar 3, 2026, 4:00 PM EST - Market closed
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $14.26M in the quarter ending September 30, 2025, with 3,575.77% growth. This brings the company's revenue in the last twelve months to $246.72M, up 37,798.31% year-over-year. In the year 2024, Keros Therapeutics had annual revenue of $3.55M with 2,250.99% growth.
Revenue (ttm)
$246.72M
Revenue Growth
+37,798.31%
P/S Ratio
1.65
Revenue / Employee
$3,008,756
Employees
82
Market Cap
408.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.55M | 3.40M | 2,250.99% |
| Dec 31, 2023 | 151.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 20.10M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ginkgo Bioworks Holdings | 170.16M |
| Enanta Pharmaceuticals | 66.98M |
| Entrada Therapeutics | 25.42M |
| LENZ Therapeutics | 17.50M |
| Armata Pharmaceuticals | 5.05M |
| Absci | 2.82M |
| Upstream Bio | 2.80M |
KROS News
- 5 days ago - Keros Therapeutics Appoints Charles Newton to its Board of Directors - GlobeNewsWire
- 13 days ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 3 months ago - Keros Therapeutics Announces Final Results of Tender Offer - GlobeNewsWire
- 3 months ago - Keros Therapeutics Announces Preliminary Results of Tender Offer - GlobeNewsWire
- 4 months ago - Keros Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital - GlobeNewsWire
- 6 months ago - Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting - GlobeNewsWire